APOL1 and focal segmental glomerulosclerosis: ,4 Significant progress in understanding the pathomechanism of APOL1-mediated kidney disease (AMKD) has yielded promising therapeutic candidates; however, there is currently no FDA-approved drug for APOL1-associated kidney disease.5, 6, 7, 8 The use of nonspecific immunosuppressants for APOL1-associated FSGS and antihypertensives for APOL1-associated HTN-CKD fail to slow the rapid progression of these common forms of kidney disease to ESKD.4